C. Gutiérrez

发表

Selective miRNA Modulation Fails to Activate HIV Replication in In Vitro Latency Models

J. Santoyo, F. Sanz‐Rodríguez, M. López-Huertas, 2019, Molecular therapy. Nucleic acids.

How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

P. L. López, Miguel Ángel Martínez, D. Podzamczer, 2021, BMC Women's Health.

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound

M. Plana, M. Muñoz-Fernández, R. Delgado, 2020, Scientific Reports.

Maraviroc reactivates HIV with potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells.

N. Madrid-Elena, S. Moreno, C. Gutiérrez, 2020, Biochemical pharmacology.

Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4+ T Cells from HIV-Infected Individuals on Suppressive Antiretroviral Therapy

M. García-Bermejo, M. López-Huertas, N. Madrid-Elena, 2018, Journal of Virology.

Higher Virological Effectiveness of NNRTI-Based Antiretroviral Regimens Containing Nevirapine or Efavirenz Compared to a Triple NRTI Regimen As Initial Therapy in HIV-1-Infected Adults

V. Abraira, C. Quereda, E. Navas, 2005, HIV clinical trials.

Expression of gut‐homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV‐1‐infected patients?

M. Muñoz-Fernandez, B. Hernández-Novoa, S. Moreno, 2015, HIV medicine.

Selective miRNA inhibition in CD8+ cytotoxic T lymphocytes enhances HIV-1 specific cytotoxic responses

Javier Santoyo-Lopez, M. García-Bermejo, M. López-Huertas, 2022, Frontiers in Immunology.

Prevalence of Primary Resistance Mutations to Integrase Inhibitors in Treatment-Naïve and -Experienced Patients Infected With B and Non-B HIV-1 Variants

Á. Holguín, B. Hernández-Novoa, S. Moreno, 2013 .

Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study

D. Podzamczer, C. Vidal, B. Rodés, 2020, AIDS Research and Therapy.

Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.

Miguel Ángel Martínez, D. Podzamczer, C. Vidal, 2020, The Journal of antimicrobial chemotherapy.

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, The Journal of infection.

CD72/CD100 and PD-1/PD-L1 markers are increased on T and B cells in HIV-1+ viremic individuals, and CD72/CD100 axis is correlated with T-cell exhaustion

M. Muñoz-Fernández, C. Gutiérrez, M. Pion, 2018, PloS one.

The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients

J. Zamora, M. Muñoz-Fernández, E. Muñoz, 2012, AIDS.

Correlation Between Different Methods to Measure Microbial Translocation and Its Association With Immune Activation in Long-Term Suppressed HIV-1–Infected Individuals

B. Hernández-Novoa, S. Moreno, A. Vallejo, 2013, Journal of acquired immune deficiency syndromes.

Effect of the Use of Galectin-9 and Blockade of the TIM-3 Receptor in the Latent Cellular Reservoir of HIV-1

N. Madrid-Elena, S. Moreno, A. Vallejo, 2020, Journal of Virology.

Effect of food on the antiviral activity of didanosine enteric‐coated capsules: a pilot comparative study *

B. Hernández-Novoa, S. Moreno, A. Antela, 2008, HIV medicine.

Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral‐experienced HIV‐infected patients

J. Martinez-Picado, B. Rodés, V. Soriano, 2005, Journal of medical virology.

Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

Coral Barbas, Santiago Moreno, C. Barbas, 2016, AIDS.

Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification

B. Clotet, J. Martinez-Picado, K. Morales-Lopetegi, 2005, Journal of Clinical Microbiology.

Fecal microbiota transplantation in HIV: A pilot placebo-controlled study

M. Osman, J. Zamora, M. Gosalbes, 2021, Nature Communications.

Blood Bacterial Profiles Associated with HIV Infection and Immune Recovery.

F. Servant, M. Ferrer, B. Lelouvier, 2020, The Journal of infectious diseases.

Analysis of the dysregulation between regulatory B and T cells (Breg and Treg) in human immunodeficiency virus (HIV)-infected patients

M. Muñoz-Fernández, C. Gutiérrez, M. Pion, 2019, PloS one.

Changes in the immune response after treatment with benznidazole versus no treatment in patients with chronic indeterminate Chagas disease.

R. López-Vélez, B. Monge-Maillo, J. Pérez-Molina, 2016, Acta tropica.

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

M. Gosalbes, A. Moya, J. Vázquez-Castellanos, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1

J. Alcamí, M. López-Huertas, M. Coiras, 2017, Scientific Reports.

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

J. Zamora, M. Muñoz-Fernández, E. Muñoz, 2011, PloS one.

Progressive cellular immune impairment leading to development of AIDS: two-year prospective study of HIV infection in drug addicts.

E. Fernandez-cruz, C. Gutiérrez, M. T. de la Morena, 1988, Clinical and experimental immunology.

Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants.

Á. Holguín, B. Hernández-Novoa, S. Moreno, 2013, HIV clinical trials.

Physicians' opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain.

P. L. López, Miguel Ángel Martínez, D. Podzamczer, 2019, The Journal of antimicrobial chemotherapy.

Dynamics of the HIV-1 latent reservoir after discontinuation of the intensification of antiretroviral treatment: results of two clinical trials

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, AIDS.

High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir

V. Abraira, S. Moreno, M. Pérez-Elías, 2005, AIDS.

High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use.

E. Ruiz-Mateos, M. Leal, L. Tarancón-Díez, 2019, Virus research.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.

S. Moreno, M. Pérez-Elías, A. Antela, 2003, AIDS.

The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.

J. Zamora, M. Muñoz-Fernández, B. Hernández-Novoa, 2013, The Journal of infection.

Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.

Miguel Ángel Martínez, D. Podzamczer, C. Vidal, 2020, The Journal of antimicrobial chemotherapy.

An updated examination of the perception of barriers for pharmacogenomics implementation and the usefulness of drug/gene pairs in Latin America and the Caribbean

M. J. Fresnadillo Martínez, Camila Calfío, L. Quiñones, 2023, Frontiers in Pharmacology.

Expression of gut‐homing β7 receptor on T cells: surrogate marker for microbial translocation in suppressed HIV‐1‐infected patients?

C. Gutiérrez, N. Madrid, M. Abad-Fernández, 2015, HIV medicine.